

18 December 2018

RESPIRI



RESPIRI FAST TRACKS PRODUCT PORTFOLIO DEVELOPMENT WITH INDUSTRIAL WORKPLACE ASTHMA SOLUTION

Respiri Limited (ASX:RSH) today announced that the company is currently in negotiations to develop an industrial workplace asthma solution that will fast track the stand-alone wheeze monitor and customised enterprise platform, expanding its product portfolio and allowing Respiri to capitalise on a major market opportunity.

The company is progressing more than one MOU to trial the solution with wheezo™ and then determine the key details for the development of the stand-alone wheeze monitor and enterprise platform that will utilise Respiri's machine learning model, currently being implemented in the wheezo™ platform.

Exposure to substances commonly found in a variety of industrial workplaces can lead to asthma episodes if the worker has uncontrolled asthma, is not aware that they have the condition or the substances trigger asthma. The potential partners see an opportunity to support existing Occupational Health and Safety practices and reduce risk by proactively leveraging Respiri's technology and ability to measure the typical symptom of asthma, wheezing, and then correlate that 'wheeze rate' with other symptoms and triggers of asthma. Respiri monitoring will help identify people with asthma and potentially prevent life-threatening asthma episodes in the workplace.

Under the leadership of Professor Bruce Thompson, the company is currently expanding its product portfolio with development of the overnight monitor to be complemented by the stand-alone monitor and enterprise platform for industrial and research applications.

Respiri looks forward to updating the market on material developments with the industrial workplace asthma opportunity.

--END--

Contact:
Mario Gattino
CEO & Director
+61 3 9653 9160

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.